Medifacts Acquires SpaceLabs Healthcare Clinical Trials Services Division
ROCKVILLE, MD, SEATTLE, WA (USA) June 23, 2009
-MEDIFACTS INTERNATIONAL, INC. a leading global cardiovascular core lab announced today the acquisition of the Clinical Trials Services division of Spacelabs Healthcare, Inc. (“CTS”). Financial terms of the transaction were not disclosed.
The combination of Medifacts International and CTS, a global provider of integrated, centralized cardiovascular safety and diagnostic services to the pharmaceutical and biotechnology industries, brings together Medifacts’ industry-leading scientific and regulatory expertise, global logistics and support infrastructure with CTS’ demonstrated commitment to technology, service excellence and client-focused solutions.
Michael Woehler, PhD, President and CEO of Medifacts said: “This combination brings together two highly motivated teams that share a passion for delivering the highest quality service, and creates the broadest product offering of cardiac safety and efficacy services for Phase I through IV clinical trials to pharmaceutical, biotech and medical device manufacturers worldwide. We are delighted to welcome the CTS team into the Medifacts organization today.”
Dr Woehler added, “The combination enhances our existing client relationships and creates an even stronger partner for new and existing clients alike. Medifacts is committed to assisting companies navigate the complex regulatory and scientific requirements throughout the drug development clinical trial process in a fast and cost efficient manner. Our acquisition of the CTS business today is a further demonstration of that commitment.”
John Carpentier, General Manager of CTS commented, “Through the combination with Medifacts, we will be able to provide existing and future clients with a wide array of ECG, Holter, and Blood Pressure technologies supported by the industry's most experienced technologists and scientific experts. I am excited to be joining the Medifacts group and look forward to serving all of our clients as a part of this world class team.”
About MEDIFACTS
Driven by best-in-class Science, Technology, and Service Quality, Medifacts International has become a global leader providing ECG, Holter, Ambulatory Blood Pressure Monitoring, Spirometry, Glucometry, Pulse Wave Analysis and related services to pharmaceutical, biotech and medical device companies.
Medifacts International’s scientific expertise, proprietary WebHeart® technology, global presence and recognized quality leadership has established Medifacts as one of the top 3 providers worldwide in comprehensive cardiac safety and efficacy services
About SPACELABS HEALTHCARE, INC.
Spacelabs Healthcare, Inc.
is an international developer, manufacturer and distributor of medical equipment and services including patient monitoring solutions, anesthesia delivery and ventilation systems, diagnostic cardiology solutions and supplies and accessories selling to hospitals, clinics and physicians offices. Additionally, the company provides ECG laboratory services to pharmaceutical companies undertaking clinical trials, whereby patient ECG data is recorded, analyzed, tabulated and interpreted.
The company has established brand names in both medical devices and medical services such as "Spacelabs," "Blease," Del Mar Reynolds and "Dolphin." It employs approximately 1,500 personnel in its offices located in the United States, UK, Canada, France, Germany, Finland, India and Singapore.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
